These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 405441)

  • 21. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes.
    Nachman R; Levine R; Jaffe EA
    J Clin Invest; 1977 Oct; 60(4):914-21. PubMed ID: 70434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. von Willebrand factor: characterization of interaction among von Willebrand factor, ristocetin and platelet.
    Hashimoto S; Suzuki K
    Nihon Ketsueki Gakkai Zasshi; 1979 Dec; 42(6):851-63. PubMed ID: 317771
    [No Abstract]   [Full Text] [Related]  

  • 24. Family studies of patients with reduced ristocetin aggregation and abnormalities of factor VIII and/or platelet function.
    Ekert H; Ananthakrishnan R; Muntz RH; Dowling S; D'Souza S
    Thromb Haemost; 1976 Aug; 36(1):78-85. PubMed ID: 1087478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma components which interfere with ristocetin-induced platelet aggregation.
    Baugh RF; Brown JE; Hougie C
    Thromb Diath Haemorrh; 1975 Jun; 33(3):540-6. PubMed ID: 1080300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor.
    Read MS; Shermer RW; Brinkhous KM
    Proc Natl Acad Sci U S A; 1978 Sep; 75(9):4514-8. PubMed ID: 309134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Support of ristocetin-induced platelet aggregation by procoagulant-inactive and plasmin-cleaved forms of human factor VIII/von Willebrand factor.
    Andersen JC; Switzer ME; McKee PA
    Blood; 1980 Jan; 55(1):101-8. PubMed ID: 6444272
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibody nature of circulating inhibitor of plasma von Willebrand factor.
    Stratton RD; Wagner RH; Webster WP; Brinkhous KM
    Proc Natl Acad Sci U S A; 1975 Oct; 72(10):4167-71. PubMed ID: 812091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of porcine von Willebrand factor (platelet aggregating factor) with human platelets.
    Finlay TH; Marcus DL; Kowalski S; Silber P
    Biochim Biophys Acta; 1981 Jan; 672(1):79-88. PubMed ID: 6260227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Purification and properties of porcine platelet aggregating factor.
    Marcus DL; Johnson AJ; Finlay TH
    Biochim Biophys Acta; 1978 Nov; 537(1):44-61. PubMed ID: 718981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular structural studies of human factor VIII.
    McKee PA; Andersen JC; Switzer ME
    Ann N Y Acad Sci; 1975 Jan; 240():8-33. PubMed ID: 122889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of Willebrand factor in platelet - blood vessel interaction, including a discussion of resistance to atherosclerosis in pigs with von Willebrand's disease.
    Bowie EJ; Fuster V; Fass DN; Owen CA
    Philos Trans R Soc Lond B Biol Sci; 1981 Aug; 294(1072):267-79. PubMed ID: 6117890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of inhibition by trinitrophenylation of the ristocetin cofactor activity of von Willebrand factor.
    Santoro SA; Cowan JF
    Biochim Biophys Acta; 1984 Feb; 797(2):178-85. PubMed ID: 6607747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor.
    Suzuki K; Nishioka J; Hashimoto S
    Thromb Res; 1980 Feb 1-15; 17(3-4):443-52. PubMed ID: 6966083
    [No Abstract]   [Full Text] [Related]  

  • 35. Partial purification of biologically active, low molecular weight, human antihemophilic factor free of Von Willebrand factor. I. Partial characterization and evidence for disulfide bond(s) susceptible to limited reduction.
    Harris RB; Newman J; Johnson AJ
    Biochim Biophys Acta; 1981 May; 668(3):456-70. PubMed ID: 6786356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel core fractionation process of human plasma by expanded bed adsorption chromatography.
    Lihme A; Hansen MB; Andersen IV; Burnouf T
    Anal Biochem; 2010 Apr; 399(1):102-9. PubMed ID: 19995544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation and properties of bovine factor VIII (antihemophilic factor).
    Vehar GA; Davie EW
    Biochemistry; 1980 Feb; 19(3):401-10. PubMed ID: 7356933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma.
    Lian EC; Mui PT; Siddiqui FA; Chiu LL
    Thromb Res; 1984 Jan; 33(1):69-76. PubMed ID: 6420930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dispersity of human factor VIII--Von Willebrand factor.
    van Mourik JA; Bolhuis PA
    Thromb Res; 1978 Jul; 13(1):15-24. PubMed ID: 308712
    [No Abstract]   [Full Text] [Related]  

  • 40. Identity of bovine platelet aggregation factor and ristocetin-Willebrand factor.
    Kalogjera V; Owen WG
    Thromb Res; 1978 Nov; 13(5):857-64. PubMed ID: 311087
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.